{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T07:40:25Z","timestamp":1781163625393,"version":"3.54.1"},"reference-count":84,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Brain Research"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.brainres.2024.149342","type":"journal-article","created":{"date-parts":[[2024,11,19]],"date-time":"2024-11-19T05:01:37Z","timestamp":1731992497000},"page":"149342","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Exploring DPP IV inhibitors for Alzheimer\u2019s disease: Bridging diabetes and neurodegeneration"],"prefix":"10.1016","volume":"1848","author":[{"given":"Swagata","family":"Pattanaik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shakti Ketan","family":"Prusty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pratap Kumar","family":"Sahu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"106","key":"10.1016\/j.brainres.2024.149342_b0005","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.biopha.2018.06.147","article-title":"A molecular approach in drug development for Alzheimer\u2019s disease","volume":"1","author":"Agatonovic-Kustrin","year":"2018","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.brainres.2024.149342_b0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12929-017-0379-z","article-title":"Oxidative toxicity in diabetes and Alzheimer\u2019s disease: mechanisms behind ROS\/RNS generation","volume":"24","author":"Ahmad","year":"2017","journal-title":"J. Biomed. Sci."},{"issue":"64","key":"10.1016\/j.brainres.2024.149342_b0015","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.neubiorev.2016.03.005","article-title":"Diabetes and Alzheimer\u2019s disease crosstalk","volume":"1","author":"Baglietto-Vargas","year":"2016","journal-title":"Neurosci. Biobehav. Rev."},{"issue":"1","key":"10.1016\/j.brainres.2024.149342_b0020","doi-asserted-by":"crossref","first-page":"83","DOI":"10.58502\/DTT.24.0030","article-title":"Anti-inflammatory effects of dipeptidyl peptidase-4 inhibitors and their therapeutic application for Parkinson's disease","volume":"3","author":"Bang","year":"2024","journal-title":"Drug Targets Therap."},{"issue":"5","key":"10.1016\/j.brainres.2024.149342_b0025","first-page":"161","article-title":"Insulin in the brain: its pathophysiological implications for States related with central insulin resistance, type 2 diabetes and Alzheimer\u2019s disease","volume":"9","author":"Bl\u00e1zquez","year":"2014","journal-title":"Front. Endocrinol."},{"issue":"88","key":"10.1016\/j.brainres.2024.149342_b0030","article-title":"Cognitive and metabolic outcomes of vildagliptin addition to the therapy in patients with type 2 diabetes mellitus: 26 week follow-up study","volume":"1","author":"Bulut","year":"2020","journal-title":"Arch. Gerontol. Geriatr."},{"key":"10.1016\/j.brainres.2024.149342_b0035","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s10571-015-0233-3","article-title":"Role of RAGE in Alzheimer\u2019s disease","volume":"36","author":"Cai","year":"2016","journal-title":"Cell. Mol. Neurobiol."},{"issue":"6","key":"10.1016\/j.brainres.2024.149342_b0040","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.jalz.2016.02.010","article-title":"Neuroinflammation in Alzheimer's disease: current evidence and future directions","volume":"12","author":"Calsolaro","year":"2016","journal-title":"Alzheimers Dement."},{"issue":"7","key":"10.1016\/j.brainres.2024.149342_b0045","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1038\/s41374-019-0231-z","article-title":"The amyloid cascade and Alzheimer\u2019s disease therapeutics: Theory versus observation","volume":"99","author":"Castellani","year":"2019","journal-title":"Lab. Invest."},{"issue":"157","key":"10.1016\/j.brainres.2024.149342_b0050","article-title":"DPP-4 inhibitor improves learning and memory deficits and AD-like neurodegeneration by modulating the GLP-1 signaling","volume":"1","author":"Chen","year":"2019","journal-title":"Neuropharmacology"},{"issue":"3","key":"10.1016\/j.brainres.2024.149342_b0055","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.13005\/bpj\/2462","article-title":"Effect of Vildagliptin on Cognitive Deficits in an Experimental Model of Alzheimer\u2019s Disease","volume":"15","author":"Dash","year":"2022","journal-title":"Biomedical and Pharmacology Journal."},{"issue":"2","key":"10.1016\/j.brainres.2024.149342_b0060","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1007\/s10616-019-00312-7","article-title":"Vildagliptine protects SH-SY5Y human neuron-like cells from A \u03b2 1\u201342 induced toxicity, in vitro","volume":"71","author":"Dokumac\u0131","year":"2019","journal-title":"Cytotechnology"},{"issue":"696","key":"10.1016\/j.brainres.2024.149342_b0065","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.neulet.2018.12.041","article-title":"Sitagliptin protects the cognition function of the Alzheimer\u2019s disease mice through activating glucagon-like peptide-1 and BDNF-TrkB signalings","volume":"23","author":"Dong","year":"2019","journal-title":"Neurosci. Lett."},{"issue":"13","key":"10.1016\/j.brainres.2024.149342_b0070","article-title":"The mechanism and efficacy of GLP-1 receptor agonists in the treatment of Alzheimer\u2019s disease","volume":"17","author":"Du","year":"2022","journal-title":"Front. Endocrinol."},{"issue":"769","key":"10.1016\/j.brainres.2024.149342_b0075","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.ejphar.2015.11.033","article-title":"Favorable effects of vildagliptin on metabolic and cognitive dysfunctions in streptozotocin-induced diabetic rats","volume":"15","author":"El Batsh","year":"2015","journal-title":"Eur. J. Pharmacol."},{"issue":"352","key":"10.1016\/j.brainres.2024.149342_b0080","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.taap.2018.05.035","article-title":"Neuroprotective effect of linagliptin against cuprizone-induced demyelination and behavioural dysfunction in mice: a pivotal role of AMPK\/SIRT1 and JAK2\/STAT3\/NF-\u03baB signaling pathway modulation","volume":"1","author":"Elbaz","year":"2018","journal-title":"Toxicol. Appl. Pharmacol."},{"issue":"2","key":"10.1016\/j.brainres.2024.149342_b0085","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1093\/ijnp\/pyaa078","article-title":"Alogliptin attenuates lipopolysaccharide-induced neuroinflammation in mice through modulation of TLR4\/MYD88\/NF-\u03baB and miRNA-155\/SOCS-1 signaling pathways","volume":"24","author":"El-Sahar","year":"2021","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"5","key":"10.1016\/j.brainres.2024.149342_b0090","doi-asserted-by":"crossref","first-page":"508","DOI":"10.2174\/1570159X15666170720095240","article-title":"Microglia and astrocytes in Alzheimer's disease: implications for therapy","volume":"16","author":"Fakhoury","year":"2018","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.brainres.2024.149342_b0095","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13195-015-0130-5","article-title":"The impact of diabetes on cognitive decline: potential vascular, metabolic, and psychosocial risk factors","volume":"7","author":"Feinkohl","year":"2015","journal-title":"Alzheimers Res. Ther."},{"issue":"239","key":"10.1016\/j.brainres.2024.149342_b0100","article-title":"Incretin-based drugs as potential therapy for neurodegenerative diseases: current status and perspectives","volume":"1","author":"Ferrari","year":"2022","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.brainres.2024.149342_b0105","series-title":"Autophagy: Biology and Diseases","first-page":"179","article-title":"Oxidative stress and autophagy","author":"Gao","year":"2019"},{"issue":"4","key":"10.1016\/j.brainres.2024.149342_b0110","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1111\/dom.12432","article-title":"Sitagliptin, a dipeptidyl peptidase\u20104 inhibitor, improves recognition memory, oxidative stress and hippocampal neurogenesis and upregulates key genes involved in cognitive decline","volume":"17","author":"Gault","year":"2015","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.brainres.2024.149342_b0115","first-page":"1","article-title":"Crosstalk between Alzheimer\u2019s disease and diabetes: a focus on anti-diabetic drugs","volume":"19","author":"Goodarzi","year":"2023","journal-title":"Metab. Brain Dis."},{"issue":"147","key":"10.1016\/j.brainres.2024.149342_b0120","article-title":"More than just an enzyme: Dipeptidyl peptidase-4 (DPP-4) and its association with diabetic kidney remodelling","volume":"1","author":"Gupta","year":"2019","journal-title":"Pharmacol. Res."},{"issue":"7","key":"10.1016\/j.brainres.2024.149342_b0125","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1093\/brain\/awy132","article-title":"The cholinergic system in the pathophysiology and treatment of Alzheimer\u2019s disease","volume":"141","author":"Hampel","year":"2018","journal-title":"Brain"},{"issue":"109","key":"10.1016\/j.brainres.2024.149342_b0130","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.biopha.2018.10.064","article-title":"The neurovascular protective effect of alogliptin in murine MCAO model and brain endothelial cells","volume":"1","author":"Hao","year":"2019","journal-title":"Biomed. Pharmacother."},{"issue":"2","key":"10.1016\/j.brainres.2024.149342_b0135","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0228750","article-title":"The dipeptidyl peptidase-4 inhibitor, linagliptin, improves cognitive impairment in streptozotocin-induced diabetic mice by inhibiting oxidative stress and microglial activation","volume":"15","author":"Ide","year":"2020","journal-title":"PLoS One"},{"issue":"123","key":"10.1016\/j.brainres.2024.149342_b0140","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.diabres.2016.12.010","article-title":"The effects of sitagliptin, a DPP-4 inhibitor, on cognitive functions in elderly diabetic patients with or without Alzheimer\u2019s disease","volume":"1","author":"Isik","year":"2017","journal-title":"Diabetes Res. Clin. Pract."},{"issue":"2","key":"10.1016\/j.brainres.2024.149342_b0145","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.sjbs.2019.12.028","article-title":"Diabetes as a risk factor for Alzheimer\u2019s disease in the Middle East and its shared pathological mediators","volume":"27","author":"Jayaraj","year":"2020","journal-title":"Saudi J. Biol. Sci."},{"issue":"15","key":"10.1016\/j.brainres.2024.149342_b0150","article-title":"Neuroprotective effects of dipeptidyl peptidase 4 inhibitor on Alzheimer\u2019s disease: a narrative review","volume":"9","author":"Jiang","year":"2024","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.brainres.2024.149342_b0155","article-title":"Memory loss in Alzheimer's disease","author":"John","year":"2022","journal-title":"Dialogues Clin. Neurosci."},{"issue":"4","key":"10.1016\/j.brainres.2024.149342_b0160","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1007\/s10787-019-00580-x","article-title":"Activation of microglia and astrocytes: a roadway to neuroinflammation and Alzheimer\u2019s disease","volume":"27","author":"Kaur","year":"2019","journal-title":"Inflammopharmacology"},{"issue":"8","key":"10.1016\/j.brainres.2024.149342_b0165","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0183565","article-title":"Involvement of insulin resistance in D-galactose-induced age-related dementia in rats: Protective role of metformin and saxagliptin","volume":"12","author":"Kenawy","year":"2017","journal-title":"PLoS One"},{"issue":"392","key":"10.1016\/j.brainres.2024.149342_b0170","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1007\/s00210-019-01616-3","article-title":"Combined vildagliptin and memantine treatment downregulates expression of amyloid precursor protein, and total and phosphorylated tau in a rat model of combined Alzheimer\u2019s disease and type 2 diabetes","volume":"4","author":"Khalaf","year":"2019","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol."},{"issue":"7","key":"10.1016\/j.brainres.2024.149342_b0175","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1111\/cns.12404","article-title":"DPP\u20104 inhibitor linagliptin attenuates A\u03b2\u2010induced cytotoxicity through activation of AMPK in neuronal cells","volume":"21","author":"Kornelius","year":"2015","journal-title":"CNS Neurosci. Ther."},{"issue":"72","key":"10.1016\/j.brainres.2024.149342_b0180","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.neuropharm.2013.04.008","article-title":"Saxagliptin: a dipeptidyl peptidase-4 inhibitor ameliorates streptozotocin induced Alzheimer's disease","volume":"1","author":"Kosaraju","year":"2013","journal-title":"Neuropharmacology"},{"issue":"12","key":"10.1016\/j.brainres.2024.149342_b0185","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1111\/jphp.12148","article-title":"Vildagliptin: an anti-diabetes agent ameliorates cognitive deficits and pathology observed in streptozotocin-induced Alzheimer's disease","volume":"65","author":"Kosaraju","year":"2013","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.brainres.2024.149342_b0190","doi-asserted-by":"crossref","first-page":"6074","DOI":"10.1007\/s12035-016-0125-7","article-title":"Linagliptin, a dipeptidyl peptidase-4 inhibitor, mitigates cognitive deficits and pathology in the 3xTg-AD mouse model of Alzheimer\u2019s disease","volume":"54","author":"Kosaraju","year":"2017","journal-title":"Mol. Neurobiol."},{"issue":"30","key":"10.1016\/j.brainres.2024.149342_b0195","doi-asserted-by":"crossref","first-page":"3283","DOI":"10.2174\/0929867324666170705123509","article-title":"Modulators of acetylcholinesterase activity: From Alzheimer's disease to anti-cancer drugs","volume":"24","author":"Lazarevic-Pasti","year":"2017","journal-title":"Curr. Med. Chem."},{"issue":"6","key":"10.1016\/j.brainres.2024.149342_b0200","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1002\/ddr.21567","article-title":"Activation of Nrf2 signaling by sitagliptin and quercetin combination against \u03b2\u2010amyloid induced Alzheimer's disease in rats","volume":"80","author":"Li","year":"2019","journal-title":"Drug Dev. Res."},{"issue":"3","key":"10.1016\/j.brainres.2024.149342_b0205","first-page":"4113","article-title":"Vildagliptin prevents cognitive deficits and neuronal apoptosis in a rat model of Alzheimer's disease","volume":"17","author":"Ma","year":"2018","journal-title":"Mol. Med. Rep."},{"issue":"159","key":"10.1016\/j.brainres.2024.149342_b0210","article-title":"Vildagliptin restores cognitive function and mitigates hippocampal neuronal apoptosis in cisplatin-induced chemo-brain: Imperative roles of AMPK\/Akt\/CREB\/BDNF signaling cascades","volume":"1","author":"Mahmoud","year":"2023","journal-title":"Biomed. Pharmacother."},{"issue":"5","key":"10.1016\/j.brainres.2024.149342_b0215","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.3390\/ijms23052687","article-title":"Alzheimer\u2019s disease as type 3 diabetes: Common pathophysiological mechanisms between Alzheimer\u2019s disease and type 2 diabetes","volume":"23","author":"Michailidis","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.brainres.2024.149342_b0220","doi-asserted-by":"crossref","first-page":"745","DOI":"10.4103\/1673-5374.249217","article-title":"Repositioning of dipeptidyl peptidase-4 inhibitors and glucagon like peptide-1 agonists as potential neuroprotective agents","volume":"14","author":"Mousa","year":"2019","journal-title":"Neural Regen. Res."},{"issue":"10","key":"10.1016\/j.brainres.2024.149342_b0225","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.3390\/ijms20102539","article-title":"The dipeptidyl peptidase-4 inhibitor linagliptin ameliorates high-fat induced cognitive decline in tauopathy model mice","volume":"20","author":"Nakaoku","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"89","key":"10.1016\/j.brainres.2024.149342_b0230","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.neuropharm.2014.10.007","article-title":"Saxagliptin: a novel antiparkinsonian approach","volume":"1","author":"Nassar","year":"2015","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.brainres.2024.149342_b0235","article-title":"Antidiabetic agents as a novel treatment for Alzheimer\u2019s and Parkinson\u2019s disease","volume":"14","author":"Nowell","year":"2023","journal-title":"Ageing Res. Rev."},{"issue":"1","key":"10.1016\/j.brainres.2024.149342_b0240","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1530\/JOE-12-0521","article-title":"DPP-4 inhibitors improve cognition and brain mitochondrial function of insulin-resistant rats","volume":"218","author":"Pintana","year":"2013","journal-title":"J Endocrinol."},{"issue":"5","key":"10.1016\/j.brainres.2024.149342_b0245","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1111\/ejn.12088","article-title":"DPP 4\u2010inhibitor improves neuronal insulin receptor function, brain mitochondrial function and cognitive function in rats with insulin resistance induced by high\u2010fat diet consumption","volume":"37","author":"Pipatpiboon","year":"2013","journal-title":"Eur. J. Neurosci."},{"issue":"69","key":"10.1016\/j.brainres.2024.149342_b0250","article-title":"Memory amelioration by hesperidin conjugated gold nanoparticles in diabetes induced cognitive impaired rats","volume":"1","author":"Pradhan","year":"2022","journal-title":"J. Drug Deliv. Sci. Technol."},{"issue":"84","key":"10.1016\/j.brainres.2024.149342_b0255","article-title":"Mechanistic study of gold nanoparticles of Vildagliptin and Vitamin E in diabetic cognitive impairment","volume":"1","author":"Pradhan","year":"2023","journal-title":"J. Drug Deliv. Sci. Technol."},{"issue":"889","key":"10.1016\/j.brainres.2024.149342_b0260","article-title":"Alogliptin reversed hippocampal insulin resistance in an amyloid-beta fibrils-induced animal model of Alzheimer's disease","volume":"15","author":"Rahman","year":"2020","journal-title":"Eur. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.brainres.2024.149342_b0265","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s12868-024-00878-9","article-title":"Diabetes mellitus and risk of incident dementia in APOE \u025b4 carriers: an updated meta-analysis","volume":"25","author":"Rashtchian","year":"2024","journal-title":"BMC Neurosci."},{"issue":"8","key":"10.1016\/j.brainres.2024.149342_b0270","doi-asserted-by":"crossref","first-page":"712","DOI":"10.2174\/1567205012666150701103107","article-title":"Neurobiology of Alzheimer\u2019s disease: integrated molecular, physiological, anatomical, biomarker, and cognitive dimensions","volume":"12","author":"Raskin","year":"2015","journal-title":"Curr. Alzheimer Res."},{"issue":"6","key":"10.1016\/j.brainres.2024.149342_b0275","doi-asserted-by":"crossref","first-page":"926","DOI":"10.2174\/1570159X15666170116143743","article-title":"The amyloid cascade hypothesis in Alzheimer's disease: it's time to change our mind","volume":"15","author":"Ricciarelli","year":"2017","journal-title":"Curr. Neuropharmacol."},{"issue":"333","key":"10.1016\/j.brainres.2024.149342_b0280","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.taap.2017.08.005","article-title":"SGLT2-inhibitor and DPP-4 inhibitor improve brain function via attenuating mitochondrial dysfunction, insulin resistance, inflammation, and apoptosis in HFD-induced obese rats","volume":"15","author":"Sa-Nguanmoo","year":"2017","journal-title":"Toxicol. Appl. Pharmacol."},{"issue":"10284","key":"10.1016\/j.brainres.2024.149342_b0285","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1016\/S0140-6736(20)32205-4","article-title":"Alzheimer's disease","volume":"397","author":"Scheltens","year":"2021","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.brainres.2024.149342_b0290","first-page":"1479","article-title":"Cholinesterase inhibitors as Alzheimer's therapeutics","volume":"20","author":"Sharma","year":"2019","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.brainres.2024.149342_b0295","series-title":"Targeting Enzymes for Pharmaceutical Development","first-page":"257","article-title":"Cholinesterase as a target for drug development in Alzheimer\u2019s disease","author":"Sharma","year":"2020"},{"issue":"195","key":"10.1016\/j.brainres.2024.149342_b0300","article-title":"Linagliptin, a DPP-4 inhibitor, ameliorates A\u03b2 (1\u201342) peptides induced neurodegeneration and brain insulin resistance (BIR) via insulin receptor substrate-1 (IRS-1) in a rat model of Alzheimer's disease","volume":"1","author":"Siddiqui","year":"2021","journal-title":"Neuropharmacology"},{"issue":"1","key":"10.1016\/j.brainres.2024.149342_b0305","doi-asserted-by":"crossref","first-page":"6","DOI":"10.3390\/biom6010006","article-title":"Tau protein hyperphosphorylation and aggregation in Alzheimer\u2019s disease and other tauopathies, and possible neuroprotective strategies","volume":"6","author":"\u0160imi\u0107","year":"2016","journal-title":"Biomolecules"},{"issue":"17","key":"10.1016\/j.brainres.2024.149342_b0310","doi-asserted-by":"crossref","first-page":"5481","DOI":"10.3390\/molecules27175481","article-title":"Lipopolysaccharide-induced model of neuroinflammation: mechanisms of action, research application and future directions for its use","volume":"27","author":"Skrzypczak-Wiercioch","year":"2022","journal-title":"Molecules"},{"issue":"1","key":"10.1016\/j.brainres.2024.149342_b0315","doi-asserted-by":"crossref","first-page":"30","DOI":"10.3390\/livers2010003","article-title":"Oxidative stress in non-alcoholic fatty liver disease","volume":"2","author":"Smirne","year":"2022","journal-title":"Livers."},{"issue":"13","key":"10.1016\/j.brainres.2024.149342_b0320","article-title":"Brain insulin resistance and hippocampal plasticity: mechanisms and biomarkers of cognitive decline","volume":"31","author":"Spinelli","year":"2019","journal-title":"Front. Neurosci."},{"issue":"9","key":"10.1016\/j.brainres.2024.149342_b0325","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.3390\/ijms20092161","article-title":"Targeting apolipoprotein E for Alzheimer\u2019s disease: an industry perspective","volume":"20","author":"Suidan","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"9","key":"10.1016\/j.brainres.2024.149342_b0330","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.tips.2019.07.008","article-title":"Neuro-regeneration therapeutic for Alzheimer\u2019s dementia: perspectives on neurotrophic activity","volume":"40","author":"Sun","year":"2019","journal-title":"Trends Pharmacol. Sci."},{"issue":"6","key":"10.1016\/j.brainres.2024.149342_b0335","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.18203\/2319-2003.ijbcp20172242","article-title":"Study of the effect of vildagliptin, a DPP-IV inhibitor on learning and memory dysfunction of diabetic rats","volume":"6","author":"Swain","year":"2017","journal-title":"Internat. J. Basic Clin. Pharmacol."},{"key":"10.1016\/j.brainres.2024.149342_b0340","article-title":"Pathophysiology and management of Alzheimer\u2019s disease: An overview","author":"Thakur","year":"2018","journal-title":"J. Anal Pharm. Res."},{"key":"10.1016\/j.brainres.2024.149342_b0345","article-title":"Repurposing antidiabetic drugs for Alzheimer's disease: A review of preclinical and clinical evidence and overcoming challenges","volume":"21","author":"Tran","year":"2024","journal-title":"Life Sci."},{"issue":"5","key":"10.1016\/j.brainres.2024.149342_b0350","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1097\/HJH.0000000000000529","article-title":"Sitagliptin attenuated brain damage and cognitive impairment in mice with chronic cerebral hypo-perfusion through suppressing oxidative stress and inflammatory reaction","volume":"33","author":"Tsai","year":"2015","journal-title":"J. Hypertens."},{"issue":"16","key":"10.1016\/j.brainres.2024.149342_b0355","doi-asserted-by":"crossref","first-page":"5858","DOI":"10.3390\/ijms21165858","article-title":"Revisiting the amyloid cascade hypothesis: from anti-A\u03b2 therapeutics to auspicious new ways for Alzheimer\u2019s disease","volume":"21","author":"Uddin","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"124","key":"10.1016\/j.brainres.2024.149342_b0360","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.ijbiomac.2018.11.104","article-title":"Attenuation of oxidative stress induced mitochondrial dysfunction and cytotoxicity in fibroblast cells by sulfated polysaccharide from Padina gymnospora","volume":"1","author":"Vasantharaja","year":"2019","journal-title":"Int. J. Biol. Macromol."},{"issue":"1","key":"10.1016\/j.brainres.2024.149342_b0365","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1007\/s11064-019-02750-3","article-title":"NMDA receptors in astrocytes","volume":"45","author":"Verkhratsky","year":"2020","journal-title":"Neurochem. Res."},{"issue":"6","key":"10.1016\/j.brainres.2024.149342_b0370","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.201810248","article-title":"Inflammasomes in neuroinflammatory and neurodegenerative diseases","volume":"11","author":"Voet","year":"2019","journal-title":"EMBO Mol. Med."},{"issue":"8","key":"10.1016\/j.brainres.2024.149342_b0375","doi-asserted-by":"crossref","first-page":"3340","DOI":"10.1021\/acschemneuro.9b00333","article-title":"Understanding the role of systemic inflammation in Alzheimer\u2019s disease","volume":"10","author":"Walker","year":"2019","journal-title":"ACS Chem. Nerosci."},{"key":"10.1016\/j.brainres.2024.149342_b0380","series-title":"Neurology: A Queen Square Textbook","first-page":"319","article-title":"Cognitive Impairment and Dementia","author":"Warren","year":"2024"},{"key":"10.1016\/j.brainres.2024.149342_b0385","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/6091014","article-title":"Neuroprotective activity of sitagliptin via reduction of neuroinflammation beyond the incretin effect: Focus on Alzheimer\u2019s disease","author":"Wici\u0144ski","year":"2018","journal-title":"Biomed Res. Int."},{"issue":"16","key":"10.1016\/j.brainres.2024.149342_b0390","doi-asserted-by":"crossref","first-page":"8881","DOI":"10.3390\/ijms25168881","article-title":"Dipeptidyl peptidase (DPP)-4 inhibitors and pituitary adenylate cyclase-activating polypeptide, a DPP-4 Substrate, extend neurite outgrowth of mouse dorsal root ganglia neurons: A promising approach in diabetic polyneuropathy treatment","volume":"25","author":"Yamaguchi","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"1517","key":"10.1016\/j.brainres.2024.149342_b0395","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.brainres.2013.04.015","article-title":"Alogliptin, a dipeptidyl peptidase-4 inhibitor, for patients with diabetes mellitus type 2, induces tolerance to focal cerebral ischemia in non-diabetic, normal mice","volume":"23","author":"Yang","year":"2013","journal-title":"Brain Res."},{"issue":"889","key":"10.1016\/j.brainres.2024.149342_b0400","article-title":"Neuroprotective effects of vildagliptin on drug induced Alzheimer's disease in rats with metabolic syndrome: role of hippocampal klotho and AKT signaling pathways","volume":"15","author":"Yossef","year":"2020","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.brainres.2024.149342_b0405","first-page":"1","article-title":"DPP-4 inhibitors sitagliptin and PF-00734, 200 mitigate dopaminergic neurodegeneration, neuroinflammation and behavioral impairment in the rat 6-OHDA model of Parkinson\u2019s disease","volume":"2","author":"Yu","year":"2024","journal-title":"GeroScience."},{"issue":"6","key":"10.1016\/j.brainres.2024.149342_b0410","first-page":"5100","article-title":"Vildagliptin, a DPP4 inhibitor, alleviates diabetes-associated cognitive deficits by decreasing the levels of apoptosis-related proteins in the rat hippocampus","volume":"15","author":"Zhang","year":"2018","journal-title":"Exp. Ther. Med."},{"issue":"776","key":"10.1016\/j.brainres.2024.149342_b0415","article-title":"Vildagliptin improves neurological function by inhibiting apoptosis and ferroptosis following intracerebral hemorrhage in mice","volume":"17","author":"Zhang","year":"2022","journal-title":"Neurosci. Lett."},{"issue":"373","key":"10.1016\/j.brainres.2024.149342_b0420","article-title":"DPP-4 inhibition by linagliptin ameliorates age-related mild cognitive impairment by regulating microglia polarization in mice","volume":"1","author":"Zhuge","year":"2024","journal-title":"Exp. Neurol."}],"container-title":["Brain Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006899324005973?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006899324005973?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T01:24:12Z","timestamp":1768353852000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006899324005973"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":84,"alternative-id":["S0006899324005973"],"URL":"https:\/\/doi.org\/10.1016\/j.brainres.2024.149342","relation":{},"ISSN":["0006-8993"],"issn-type":[{"value":"0006-8993","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Exploring DPP IV inhibitors for Alzheimer\u2019s disease: Bridging diabetes and neurodegeneration","name":"articletitle","label":"Article Title"},{"value":"Brain Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.brainres.2024.149342","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"149342"}}